Semaglutide

Semaglutide: The core molecule is now off-patent in India (as of March 20th) BUT the US and EU markets remain locked behind "Patent Thickets" until many years.

The biggest risk for firms today isn't only the science, but also the Legal + Supply Chain overlap.

I can help your company navigate this by providing:

✅ IP Due Diligence: Auditing your FTO so you don't trip over device or SNAC patents.

✅ Verified Sourcing: Connecting you with top-tier API/Intermediate manufacturers (Semaglutide, SNAC, Tirzepatide) that meet global compliance standards.

Success in the peptide space requires a clean IP pedigree. Let’s secure yours NOW.

hashtag#Biopharma hashtag#Generics hashtag#PatentStrategy hashtag#Peptides hashtag#SupplyChainSecurity